Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Gastrointestinal 2Dermatologic 2CNS 2Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Melanoma 250Uveal Melanoma 29Neoplasm Metastasis 22Skin Neoplasms 17Brain Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Merkel Cell 10Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Basal Cell 4Sarcoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2

Interventions

Cyclophosphamide 6pembrolizumab 3Filgrastim 3fludarabine 2Nivolumab 2Mesna 2Ipilimumab 2Ifosfamide 2Gemcitabine 2Etoposide 2Docetaxel 2Cryosurgery 2Carboplatin 2tocilizumab 1tipifarnib 1tanespimycin 1poly ICLC 1montanide ISA 51 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1flt3 ligand protein 1entinostat 1dostarlimab 1cc-486 1X-Rays 1Thrombopoietin 1Therapeutics 1Thalidomide 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × Ipilimumab × Dermatologic × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡